Compare AbCellera Biologics Inc (ABCL) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Norfolk Southern Corporation — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Norfolk Southern Corporation trades at $319.48 (market cap $72.49B). The key difference: Norfolk Southern Corporation is far larger — about 30.8× AbCellera Biologics Inc's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NSC | |
|---|---|---|
Market Cap | $2.35B | $72.49B |
Sector | Health | Technology |
52-Week High | $8.12 | $325.68 |
52-Week Low | $2.78 | $259.49 |
Enterprise Value | $1.99B | $88.25B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Norfolk Southern (NSC) trades at $321.9, down 0.25% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $337. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the ongoing merger process with Union Pacific, a key regulatory and operational focus.
The outlook for NSC is cautiously optimistic, with potential upside from the merger and consistent earnings performance, but risks include regulatory hurdles for the merger and rich valuation multiples. Investors should weigh the strong cash flow generation against execution risks in a consolidating industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
